Microbiome and metabolic disorder in prolactinoma: intrinsic gender differences and extrinsic therapy effects
Authors' conclusion
Patients with prolactinoma have different intestinal flora than healthy individuals. In addition to the occurrence of prolactinoma and concomitant serum prolactin excess, the gender effect and administration of dopamine agonists are also involved in regulating intestinal microbiota and the metabolic status of the host.
Study context
- Population
- Patients with prolactinoma and healthy controls; fecal samples
- Participants
- 28 vs 31
- Comparison
- Patients with prolactinoma vs healthy controls
- PRLoman = 28
- Healthy controlsn = 31reference
- Outcome
- Featured intestinal microflora, patients vs healthy individuals
Methodological details16S rRNA gene sequencing, metagenomic sequencing
- 16S rRNA gene sequencing
- Metagenomic sequencing
Main finding
As reported in the abstract
- Agathobacter, Blautia, Dorea, Fusicatenibacter and Mediterraneibacter were prominent in the PRLoma group
Observational data: associations, not effects.
Further findings
Gut species and metabolic disorders in male patients
- Bilophila wadsworthia, Clostridium sp. CAG:7, Megasphaera elsdenii and Mycoplasma sp. CAG:472 independently associated with metabolic disorders in male patients
- Effect may result from plasma xylose, glycine to serine ratio, N2-acetyl, N6, N6-dimethyllysine levels and cholesterol to oleoyl-linoleoyl-glycerol (18:1 to 18:2) ratio
Effect of dopamine agonists on gut microbiome
- Dopamine agonists reduced harmful species such as Fusobacterium mortiferum, Bacteroides fragilis and Ruminococcus biciculans, potentially contributing to improved metabolic status
Original publication
Microbiome and metabolic disorder in prolactinoma: intrinsic gender differences and extrinsic therapy effects. Pituitary. Published 3 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →